Molecular Biosystems FS069 contrast agent: 90% of patients show improved echocardiography imaging.
This article was originally published in The Gray Sheet
MOLECULAR BIOSYSTEMS' FS069 ENHANCES ECHOCARDIOGRAPHY IMAGES IN 90% OF PATIENTS in a Phase III trial of the ultrasound imaging agent, the company reports in a July 17 press release. Use of FS069 (perfluoropentane encapsulated microspheres) improved endocardial border delineating (EBD) and left ventricular opacification (LVO) in 90% of patients, the firm says. In addition, FS069 showed statistically significant (p<.0001) improvement in EBD, LVO and Doppler signal enhancement compared to MBI's first approved contrast agent, Albunex (albumin-based ultrasound microspheres).
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.